Aroa Biosurgery Limited (ASX:ARX)

Market Cap	198.65M +17.5%
Revenue (ttm)	79.26M +18.4%
Net Income	-1.60M
EPS	-0.00
Shares Out	345.48M
PE Ratio	n/a
Forward PE	44.12
Dividend	n/a
Ex-Dividend Date	n/a

Volume	109,050
Average Volume	90,132
Open	0.5950
Previous Close	0.5800
Day's Range	0.5750 - 0.5950
52-Week Range	0.3500 - 0.8000
Beta	0.80
RSI	38.42
Earnings Date	May 31, 2026

About Aroa Biosurgery

Aroa Biosurgery Limited develops, manufactures, and sells medical devices for wound and soft tissue repair using extracellular matrix (ECM) technology in the United States and internationally. Its products include Endoform Natural and Endoform Antimicrobial Restorative Bioscaffold for treating acute and chronic wounds; Myriad Matrix, an engineered ECM for soft tissue repair, reinforcement, and complex wounds; Myriad Morcells, a morcellized (powdered) format of Myriad Matrix for soft tissue repair and complex wounds; Myriad Morcells Fine that de...

• Industry: Medical Devices
• Sector: Healthcare
• Founded: 2007
• Country: New Zealand
• Stock Exchange: Australian Securities Exchange
• Ticker Symbol: ARX

Financial Performance

In fiscal year 2025, Aroa Biosurgery's revenue was 84.70 million, an increase of 22.63% compared to the previous year's 69.07 million. Losses were -3.81 million, -64.12% less than in 2024.

Financial numbers in NZD